Technical Analysis for CYTK - Cytokinetics, Incorporated

Grade Last Price % Change Price Change
grade F 8.18 0.80% 0.07
CYTK closed up 0.8 percent on Friday, November 15, 2019, on 86 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CYTK trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 0.80%
Narrow Range Bar Range Contraction 0.80%
NR7 Range Contraction 0.80%
NR7-2 Range Contraction 0.80%
Wide Bands Range Expansion 0.80%

Older signals for CYTK ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Biopharmaceutical Diseases Disease Neuroscience Anatomy Serious Diseases Heart Failure Amyotrophic Lateral Sclerosis Nervous System Treatment Of Heart Failure Astellas Pharma Treatment Of Serious Diseases
Is CYTK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.94
52 Week Low 5.75
Average Volume 652,658
200-Day Moving Average 10.3341
50-Day Moving Average 11.2911
20-Day Moving Average 10.2033
10-Day Moving Average 8.9895
Average True Range 0.5798
ADX 38.82
+DI 9.6712
-DI 37.7499
Chandelier Exit (Long, 3 ATRs ) 10.7006
Chandelier Exit (Short, 3 ATRs ) 9.4594
Upper Bollinger Band 13.2649
Lower Bollinger Band 7.1417
Percent B (%b) 0.17
BandWidth 60.011957
MACD Line -0.9812
MACD Signal Line -0.7298
MACD Histogram -0.2514
Fundamentals Value
Market Cap 438.99 Million
Num Shares 53.7 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -24.06
Price-to-Sales 6.91
Price-to-Book 3.91
PEG Ratio -0.34
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.70
Resistance 3 (R3) 8.68 8.49 8.61
Resistance 2 (R2) 8.49 8.36 8.50 8.58
Resistance 1 (R1) 8.34 8.28 8.24 8.35 8.55
Pivot Point 8.15 8.15 8.10 8.16 8.15
Support 1 (S1) 7.99 8.02 7.90 8.01 7.81
Support 2 (S2) 7.80 7.94 7.81 7.78
Support 3 (S3) 7.65 7.80 7.75
Support 4 (S4) 7.66